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Abstract
Background: Bronchiolitis caused by the respiratory syncytial virus (RSV) and its related complications are common
in infants born prematurely, with severe congenital heart disease, or bronchopulmonary dysplasia, as well as in
immunosuppressed infants. There is a rich literature on the different aspects of RSV infection with a focus, for the
most part, on specific risk populations. However, there is a need for a systematic global analysis of the impact of
RSV infection in terms of use of resources and health impact on both children and adults. With this aim, we
performed a systematic search of scientific evidence on the social, economic, and health impact of RSV infection.
Methods: A systematic search of the following databases was performed: MEDLINE, EMBASE, Spanish Medical
Index, MEDES-MEDicina in Spanish, Cochrane Plus Library, and Google without time limits. We selected 421
abstracts based on the 6,598 articles identified. From these abstracts, 4 RSV experts selected the most relevant
articles. They selected 65 articles. After reading the full articles, 23 of their references were also selected. Finally,
one more article found through a literature information alert system was included.
Results: The information collected was summarized and organized into the following topics: 1. Impact on health
(infections and respiratory complications, mid- to long-term lung function decline, recurrent wheezing, asthma,
other complications such as otitis and rhino-conjunctivitis, and mortality; 2. Impact on resources (visits to primary
care and specialists offices, emergency room visits, hospital admissions, ICU admissions, diagnostic tests, and
treatments); 3. Impact on costs (direct and indirect costs); 4. Impact on quality of life; and 5. Strategies to reduce
the impact (interventions on social and hygienic factors and prophylactic treatments).
Conclusions: We concluded that 1. The health impact of RSV infection is relevant and goes beyond the acute
episode phase; 2. The health impact of RSV infection on children is much better documented than the impact on
adults; 3. Further research is needed on mid- and long-term impact of RSV infection on the adult population,
especially those at high-risk; 4. There is a need for interventions aimed at reducing the impact of RSV infection by
targeting health education, information, and prophylaxis in high-risk populations.
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Background
The respiratory syncytial virus (RSV) causes acute bron-
chiolitis (AB) and upper and lower respiratory tract infec-
tions. The risk of severe AB, and related complications,
caused by RSV, is well-known among preterm infants,
those with severe congenital heart disease (CHD), bronch-
opulmonary dysplasia (BPD), malformations, neuromus-
cular diseases and immunological disorders. AB is the
infection of the lower respiratory tract most commonly
found among newborns [1,2]. The annual incidence of AB
in newborns is 10% [3] with an admission rate between 2
and 5%, which has seen a substantial increase in recent
years [3,4]. AB risk is increasing in many clinical situa-
tions, especially in the presence of immunosuppression.
For instance, among children, those with Down syndrome
[5], cystic fibrosis [6], biliary atresia [7], or transplant pa-
tients [8] are at higher risk for complications or severe
forms of the disease than the general population. Further,
among transplant patients, the risk of organ rejection is
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greater among children with AB than those without the
condition [8]. However, despite the increased risk of these
pathologies, we are not aware of a systematic study cap-
turing the extent and relevance of their potential impact
in terms of health as well as social and healthcare
resources required.
In adults, although RSV infection was identified with
pneumonia in the 1960s, we only started to comprehend
its importance on adult respiratory infections two de-
cades ago [9-12]. In fact, some studies suggest that the
clinical impact of RSV in some adult risk populations
may be similar to that of the seasonal influenza virus
[13,14]. These risk populations include cardiorespiratory
disease patients, frail elderly, and severely immunosup-
pressed patients [10,11,15,16]. Unlike pediatric literature,
there is an important gap in knowledge about the
epidemiology of RSV infection in adult literature, [17]
though the case may be that available data on RSV infec-
tion impact are scattered among publications in different
fields.
Thus, we designed the current study with the main
objective of determining the social, economic, and health
impact of RSV infection on children and adults based on
the best available scientific evidence.
Methods
The study was designed to start with a systematic search
of scientific literature performed by an archivist specia-
lized in medical research. Then, an expert in critical
reading carried out a first screening of the citations
identified based on titles and abstracts. Selected ab-
stracts were then examined by 4 experts (two public
health specialists, one neonatologist, and one pediatric
pulmonologist) who decided on the articles most rele-
vant to the study aims.
Systematic search
The systematic search of literature examining the RSV
social, economic, and health impact was performed du-
ring the month of September, 2012 within specific pa-
rameters regarding publication year, language (English
or Spanish), field of study, population of interest, and
type of publication.
The following engines were searched for the periods
specified: MEDLINE from 1950 on, EMBASE from 1974
on, Spanish Medical Index (IME for its acronym in
Spanish) from 1970 to 2006, MEDES-MEDicina in Spanish
from 2001 on, and the latest available issue of the
Cochrane Plus Library (Number 1, 2012). To avoid
missing any articles published in Spanish journals not
indexed in IME or MEDES, we performed a search
using Google search engine and we reviewed the first
100 results returned. Terms for these database searches
included keywords closely matching the relevant medical
field headings: respiratory syncytial virus, and respiratory
syncytial pneumovirus.
We designed this non-specific but highly sensitive
search to avoid missing any relevant information. The
delimitation of the search was performed a posteriori by
selecting titles and abstracts that included information
on: a) incidence; b) impact on health (respiratory infec-
tions, asthma, mortality, otitis media, apnea, neuro-
logical involvement, cardiac involvement, and chronic
obstructive pulmonary disease (COPD); c) impact on
healthcare resources (hospital admissions, intensive care
unit (ICU) admissions, diagnostic tests, and treatments;
d) impact on direct and indirect costs; e) and strategies
to reduce the impact, such as hygienic measures and
prophylactic treatments.
Title selection
The searches identified 10,146 references of which 3,548
were duplicate titles, resulting in 6,598 references. Arti-
cles were first filtered by discarding those with no infor-
mation on RSV’s impact. This selection reduced the
number of references of interest to 876. Based on a read-
ing of these 876 abstracts, 421 were selected.
Article selection
The 421 abstract selected were sent to 4 experts with ex-
perience in clinical practice, research, and epidemiology
relative to RSV. They were asked to select articles using
as inclusion criteria the social, economic, and RSV
health impact relevance. The four experts selected 82,
77, 59, and 58 articles, respectively. From these only
those 71 articles selected by at least 2 experts were
included. Next, based on the reading of the full articles,
6 were excluded for lack of relevance to the aim of the
study. In addition to the 65 articles [18-82], 23 more
citations found in the reference lists of these 65 articles
were included for being deemed highly relevant to the
study [83-105]. After completing the search, another
highly relevant article came to our attention through a
literature information alert system and was also included
in the review [106]. In total, 89 articles were reviewed
(Figure 1). Articles were evaluated based on the scientific
evidence quality scale of the Scottish Intercollegiate
Guidelines Network (SIGN) [107]. Table 1 shows the
methodological quality of the articles selected. For the





Population-based incidence studies on RSV infection are
scarce, except in children especially in high-risk pediatric
population. There were an estimated 33.8 million (95% CI:
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19.3-46.2) new diagnoses worldwide of RSV-associated
acute lower respiratory infections (ALRI) in children
under the age of 5 (22% of total ALRI episodes), with at
least 3.4 (95% CI: 2.8–4.3) million cases requiring hospital
admission due to severity [18]. Prescott and colleagues
reported an incidence of 24 RSV infections per 1,000 live
births [19] but higher incidences are common in the
presence of prematurity, congenital heart defects, or im-
munosuppression. Recent studies have reported infection
rates of 34.9% among children with preterm birth (gesta-
tional age (GA) ≤32 weeks) [20] and 22.5% in children
under the age of 2 with severe congenital heart disease
admitted for ALRI and/or upper respiratory infections [21].
For all ages, the annual estimate of new RSV infections
is 64 million [19]. The annual RSV infection rate in
adults has been estimated between 3% and 7% in pa-
tients over 65 years of age with no comorbidities and be-
tween 4% and 10% in high-risk adults (e.g., with chronic
cardiac or lung disease) [22].
ALRI is commonly caused by RSV, either by itself or
in combination with other viral or microbial agents. A
recent study found RSV in 36.7% of children under the age
of 9 suspected of viral respiratory infection, and in 74.6% of
those who had been admitted to the hospital [23]. Studies
on adults have reported the presence of RSV in between
6.1% and 10.0% of patients hospitalized with respiratory
symptoms [22,24]. RSV infection in community-acquired
pneumonia (CAP) pediatric cases varies between 19.8% and
30.5% [25,26] and it is estimated at about 3.8% in adults
[27]. Approximately half of the cases of RSV-induced CAP
in children ≤3 years of age present with co-infection from
other viral agents. Likelihood of co-infection increases with
age (36.4% in children ≤1 years of age and 65.0% in children
between 2 and 3 years of age) [25].
Respiratory complications of RSV infection
AB is the most frequent complication derived from RSV
infection (85% of children ≤12 month-old and 31% of
children between 2 and 5 years of age, hospitalized due to
RSV infection [28,83]). Other studies report that between
61.3% and 77.5% of AB episodes in children younger than
2 years of age are RSV-related [29-32].






Google (among the first 100 hits): 14 
Duplicates: 3,548
Identified: 10,146
Articles to be assessed: 6,598 Excluded based on title: 5,722










Abstracts selected by at least 2 
experts: 71
Excluded after full reading of the article: 6
- Animal studies
- Asthma study with no RSV information
- Bronchiolitis study with no RSV information
- Palivizumab administration guidelines
- Commentary on another article included in review
- Adherence to palivizumab prophylaxis and 
strategies on how to increase itArticles included: 65
Articles included based on the reading of 
the 65 articles already in review: 23
Total articles included: 89
Articles included as latest addition based 
on information alert system : 1
Figure 1 Flow chart of study selection process. RSV: respiratory syncytial virus. IME: Spanish Medical Index (for its acronym in Spanish).
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Although in a majority of AB cases (62%), RSV is the
only virus detected [32], the presence of other viruses
is not uncommon. The evidence on the role of co-
infection on outcomes is inconsistent: whereas some
researchers associate co-infection with poorer prognosis
[25,31], others report that co-infection reduces the se-
verity of the condition [32]. Rhinovirus (RV) is the viral
agent most frequently associated with RSV (18.1%-26.1%
of AB cases with RSV in children ≤2 years of age)
[31,32]. More aggressive strategies, such as tracheal or
nasotracheal intubation, are required by pediatric AB
cases co-infected (RSV + RV) (10% of cases) than by
those infected with RSV only (7.5% of cases) [31]. In
contrast, a study reported that cases of children monoin-
fected with RSV presented with more severity at admis-
sion (42% of RSV monoinfection vs. 31% of RSV + other
viral infection) [32]. Among infants under 12 months of
age admitted for RSV-induced AB or CAP, 79% deve-
loped complications, 24% of which were considered
serious, the most frequent complication was respiratory
(60%). Complications were most frequent in preterm
infants between 33 and 35 weeks GA (93%) and with an
average age at admission of 2.7 ± 2.5 months [84].
A systematic review on the incidence of apnea in AB
episodes among infants reported that rates varied bet-
ween 0.5% and 37.5% depending on age, preterm birth,
comorbidity, and year of the study. For premature in-
fants, rates varied between 4.9% and 37.5%, which is
significantly higher than rates among term infants (0.5%
and 12.4%). Rates in infants with serious comorbidities
vary between 10% and 20.4% versus 1.2% and 4.3% in
the absence of comorbidity [33]. The reported incidence
of apnea is lower in more recent studies, varying from
20.4% in 1977 to 2.2% in 2006. This likely reflects the
improved management of the condition in more recent
years [34].
In adults, the prevalence of viral respiratory infection
in COPD exacerbations fluctuates between 22.3% and
56% [35-40] and its negative impact on lung function
and length of hospital stay is greater than that of non-
viral flare-ups including a longer recovery time (13 days
vs. 6 days) [40]. RSV involvement has been confirmed in
0.7% to 8% of COPD flare-ups [34-40]. RSV presence
has also been detected in 11% of patients admitted with
pneumonia, COPD (11%), heart failure (5%), and asthma
(7%) [22].
Research shows that RSV infection during infancy is
an independent risk factor for declined lung function
(peak expiratory flow rate measured by forced spiro-
metry) in the following years with evidence suggesting a
residual impact for as long as 18-20 years when com-
pared to controls (OR: 5.27; 95% CI: 1.60–17.40) [85].
There is evidence of recurrent wheezing episodes asso-
ciated with a history of RSV infection. The frequency of
episodes (44%-48%) may be as high as three times that
found among children with no history of RSV infection
[41,42,86,87].
RSV-associated AB in children presents very similarly
to acute asthma: wheezing, rapid breathing, inflamma-
tion of small airways, and, in many cases, respiratory
Table 1 Study design according to SIGN classifying algorithm and SIGN quality of evidence scale
Study design and quality of evidence N % References
Systematic review or Meta-analyses 21 23.6
High quality 8 [40,42,46,61,62,65,71,72]
Acceptable 13 [18,19,28,33,41,43,50,64,67,73-76]
Economic evaluation 6 6.7
High quality 6 [55,57-60,63]
Acceptable 0
Controlled trial 4 4.5
High quality 4 [52,77,78,106]
Acceptable 0
Cohort studies 18 20.2
High quality 11 [45,69,86,87,89,90,93-95,97,105]
Acceptable 7 [44,85,88,91,100,102,103]
Case-control study 5 5.6
High quality 3 [47,79,92]
Acceptable 2 [39,99]
Cross-sectional study* 35 39.8 [20-27,29-32,34-38,48,49,51,53,54,56,66,68,70,80-84,96,98,101,104]
Total 89 100
*The scientific quality of cross-sectional studies was not evaluated because it is not required by the SIGN scale.
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compromise leading to acute lung function failure [83].
In the studies reviewed here we found an association
between RSV infection in the early years and childhood
asthma [42,45,87-95]. Most studies follow patients for
the first few childhood years and significant associations
have been found with relative risk (RR) of 21.8 at a
30-month follow-up [93] and a RR of 5.4 at a 13-year
follow-up [95]. The same author published an 18-year
follow-up showing that, despite a reduction in RR
with age, the association continues to be significant at
18-years (RR: 4.3) [45]. There is also evidence of a
significant risk increase in sensitivity to environmental
allergens after RSV infection (RR: 1.8) [95].
Cardiovascular complications
Cardiovascular complications were found in 9% of in-
fants under 12 months of age admitted for RSV-induced
AB or CAP 9% [84]. A systematic review described
cardiovascular complications such as atrial and supra-
ventricular tachycardias, life-threatening arrhythmias or
cardiogenic shock. Elevated cardiac troponin levels (as
expression of myocardial damage) were found in 35% to
54% of infants with RSV infection ventilated in PICUs
and have also been found in some children with RSV
infection not requiring mechanical ventilation [73].
Electrolyte imbalance
About 19% of children under 12 months of age admitted
for RSV-induced AB or CAP presents electrolyte im-
balance [84]. Hyponatraemia with a serum sodium level
of less than 130 mmol/l was found in 11% of infants
requiring intensive care with RSV infection; and in 0.6%
of children from a less selected population, including
patients with milder disease [73].





Impact on health Respiratory infections [21,25-27,29,31,32,35,36,75,84]
Wheezing and asthma [20,22,28,41-45,51,67,75,79,83,85-95,105]
Allergic rhinoconjunctivitis [41,45,79,95]
Mortality [18,20,22,24,46,47,49-51,63,67,82]







Impact on use of resources Primary care visits [20,22,34,51]







Impact on costs Direct costs [34,41,51,55,57-63,70]
Indirect costs [41,59-63]




*The 23 references obtained from the full reading of the articles selected by the experts on the systematic search were only classified within the topic mentioned
in the article [83-105], similarly with the article included last [106].
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Central nervous system manifestations of RSV
Acute neurological signs and symptoms such as central
apneas, seizures, lethargy, feeding or swallowing difficul-
ties, abnormalities of tone or strabism, abnormalities of
the cerebrospinal fluid or the electroencephalogram were
found in 39% of RSV-positive patients on a PICU. In pa-
tients with milder disease neurological complications were
found in 1.2% of patients. Looking at the occurrence of
seizures as a manifestation of an encephalopathy, another
group found an incidence of seizures of 1.8% in patients
with RSV bronchiolitis admitted to a paediatric tertiary
referral centre [73].
Acute otitis media and allergic rhino-conjunctivitis
Acute otitis media (AOM) is often associated with RSV
infection. Between 20% and 41% of children admitted with
a primary diagnosis of RSV infection (AB or CAP) also
present with AOM [51,52]. Another study reported RSV
infection present in 56% of AOM pediatric cases hospi-
talized between 3 and 18 months [53]. In children admit-
ted for RSV infection in their first year of life, the risk of
developing allergic rhino-conjunctivitis was significantly
greater than among controls (39% vs. 15%) [41,45,95].
Mortality
The 2005 worldwide estimates of mortality caused by
RSV-associated ALRI in children under the age of 5
range between 66,000 and 199,000 deaths, with 99% of
these deaths occurring in the developing world [18]. In
developed countries, the contribution of RSV infections
to mortality in children, including preterm children, is
almost negligible but only among those without asso-
ciated complications.
A recent meta-analysis [46] calculated preterm infant
mortality at 0.04% and slightly higher (0.62%) for those
with BPD. A cohort study of 202 preterm children of 32
to 35 weeks GA who were hospitalized for RSV infection
observed no deaths [47]. In another study of 1,583 pre-
term children ≤32 weeks GA admitted with RSV infection,
one death was observed [48]. However, as a study on
nosocomial infection-related mortality among children ad-
mitted to ICU reported, when RSV infection is present in
children with serious comorbidities, mortality may exceed
25% [49]. In adults and elderly, mortality rates mirror
those of influenza and range between 4 and 8% [22,24,50]
unless in immunosuppressed individuals (e.g., leukemia or
transplant patients) where RSV-associated mortality may
reach 30-70% [50].
Impact on use of resources
Primary care visits
It has been estimated that 2.2% (1.7 million visits) of all
U.S. primary care visits of children ≤5 years of age in the
year 2000 were caused by RSV infection [51]. Other
studies confirmed that RSV-infected children pay a signifi-
cantly greater number of visits to the doctor than their
uninfected counterparts [20,34]. RSV-infected preterm
children 32-35 weeks GA have an average of 12.4 doctor
visits during their first two years of life (median = 12;
range = 1-27) for any cause and 5 visits on average
(median = 4; range = 0-14) for respiratory causes, whereas
the same data for children with no respiratory pathology
were 9.4 (median = 8; range = 0-34) and 2.9 (median = 2;
range = 0-17), respectively [34]. A multicenter Spanish
study reported that 18.8% of first AB episodes in children
under the age of 2 were diagnosed in primary care [30]. A
study comparing RSV infection in patients over the age of
65 with no comorbidity and in high-risk patients observed
a significantly higher primary care resources usage by
high-risk patients. Specifically, 15% of the first group
called the doctor and 17% went to the primary care office
vs. 23% and 29% for the high-risk group, respectively [22].
Visits to specialists
RSV-infected patients also visit a specialist more often,
especially high-risk patients with cardiopulmonary
disease. In the U.S., it is estimated that 3.2% of visits to
specialists among children ≤5 years of age are caused by
RSV [51]. Further, in RSV-infected preterm children
32-35 weeks GA visits to specialist were estimated
18.4 ± 10.6 vs. 7.5 ± 4.3 for healthy controls [41].
Emergency room visits
During their first two years of life, U.K. RSV-infected
preterm children 32-35 weeks GA visit the emergency
room an average of 3.0 times (median = 3; range = 1-6)
for any cause and 1.6 times (median = 2; range = 1-4) for
respiratory causes. These estimates are significantly
lower in the absence of respiratory disease (mean = 0.7
(median = 0; range = 0-9) and mean = 0.1 (median = 0;
range = 0-7), respectively) [34].
A multicenter Spanish study reported that 51.7% of all
first AB episodes in children <2 years of age were seen
at the emergency room [30]. In contrast, only 9% of
high-risk adults with RSV infection went to the emer-
gency room and no adults over 65 years of age and
comorbidity-free were seen in emergency rooms [22].
Hospital admissions
Admission rates in RSV-infected children vary substan-
tially by age and comorbidity. Findings in this review va-
ried between rates of 37.0 and 142.8 per 1,000 among
preterm children ≤32 weeks GA [20,47,52,96]; 57.2 and
138.0 per 1,000 in preterm children 29-32 weeks GA
[48,96]; 23.5 and 29.5 per 1,000 in term children [96,54];
and 1.8 per 1,000 in 1-4 year-olds [54]. In children ≤2 years
of age with congenital heart disease, admission rates
ranged between 38 and 80 per 1,000 [23,55]. A 2008 study
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reported that co-infection with two or more viruses in-
creased the risk of admission up to 67.2% in children with
pneumonia vs. 46.1% in the absence of co-infection [25].
Additional factors likely to increase the risk of admission
three- and four-fold include: prematurity, low birth
weight, immunosuppression, BPD, neurological issues,
being ≤10 weeks at the start of RSV season, breastfeeding
under 2 months, school-age siblings, going to daycare,
living with at least 4 adults, exposure to environmental pol-
lution or tobacco smoke, maternal tobacco use during preg-
nancy, and family history of asthma [20,21,41,47,97-99].
Risk increases substantially in the presence of two or more
of these factors [47]. Lower admission rates have been
reported in the general population (children and adults)
(0.553 per 1,000; 95% CI: 0.44-1.06) [54], although rates
vary considerably based on comorbidity. Admission rates
between 15 and 16% have been reported in high-risk
adults with RSV infection [22,24].
The number of hospitalization days due to RSV varies
substantially by age of the patient and country of residence.
Findings in the studies reviewed ranged from 1.2 to 15 in-
patient days [20-22,24,26,29,31,32,41,47,49,56,100,101]. In
children 32-35 weeks GA, the median duration was 7 days
(interquartile range = 4-10 days) [47]. In children 29-33
weeks GA the average number of days at the hospital was
7.4 ± 4.9 days and, in those 33-36 weeks GA, the average
is 7.9 ± 6.0 days [100]. Another study reported similar
data: 6.8 days for children ≤32 weeks GA and 8.4 days for
those 33-35 weeks GA [101].
In the last 10 years in Spain, hospital stays for chil-
dren <2 years of age with or without related risk factors
averaged 5-8 days [21,29], in contrast with an average of
1.2-3.8 days in the U.S. [56] and U.K. [20]. In children
under 14, average stay was similar before 18 months
(5.7 days) and after 18 months of age (5.8 days) [26]. Data
examined on adults also show substantial fluctuation, va-
rying from 3 days (range = 2-6 days) to 14 ± 8 days [22,24].
The current evidence on the role of co-infection on
the length of hospital stay is inconclusive. Some studies
found that co-infection increased the length of stay
(53.7% vs. 47.6% stayed ≥3 days; p < 0.05) [31], whereas
others found that co-infection shortened it (47.8% vs.
57.4% stayed in the hospital ≥4 days; p < 0.02) [32].
ICU admissions
Intensive Care Unit (ICU) admissions among those hospi-
talized due to RSV infection also vary according to age,
comorbidity, and country. Premature birth is also a risk
factor for ICU admission, especially in infants 33-35 weeks
GA for whom admission rates varied between 17.8% and
48.4% [47,101]. In Spain, 1.5% of children <2 years of age
with AB needed ICU admission, 3.6% in Israel [32] and
between 11.6% and 17.5% in the U.S. [30,31,56]. In Spain,
about 30.4% of children ≤2 years of age admitted for
congenital heart disease and RSV infection required ICU
admission [21]. In U.S. adults, admissions varied between
9.7% [24] and 15% in high-risk adults [22].
The mean and median stay in ICU for children under
the age of 2 was about 4 days [56,101], although it reached
a median of 10 days (range = 5-18 days) if the patient
presented with congenital heart disease [21]. In the case of
prematurity, the average stay was 7.7 days for those 33-35
weeks GA and about 6 days for those ≤32 weeks GA
[48,101]. In adults over the age of 50, the median stay
reported was 5 days (range = 3-12 days) [24].
Diagnostic tests for RSV infection and its clinical
management
A multicenter study including 5,647 children <2 years of
age with a first AB episode, reported that oxygen sa-
turation was measured in 73% of patients, chest X-ray
was performed in 31.3%, blood gases were measured in
11.8%, blood count in 22.2%, and RSV tests were per-
formed in 37.4%, of which 63.5% turned out positive.
Tests were significantly more likely to be performed if
the child was younger [30]. In the U.S., it was estimated
that children ≤5 years of age with RSV-induced respira-
tory infection received chest X-rays in 20%, 45%, and 7%
of cases when seen in primary care, emergency room,
and hospital outpatient visits, respectively [51]. Other
tests frequently performed in emergency rooms included
oxygen saturation (36%) and blood count (20%) [51].
Also in the U.S., adults with RSV-induced respiratory
infection received chest X-rays in 7% of elderly with no
comorbidity and 20% of high-risk adults [22].
Treatments
In patients ≤2 years of age with AB, oxygen was required
by the 22.1% [30]. Among those hospitalized, oxygen
was used more frequently in the presence of RSV infec-
tion than in its absence (56.3% vs. 46.7%) [56].
Between 6% and 18.3% of children hospitalized for RSV
infection required assisted ventilation [47,49,56] for a
median period of time estimated at 6 days (range = 4.13)
[48,56]. Between 3.2% and 13% of adults required assisted
ventilation [22,24]. The need for intubation in pediatric
cases admitted for AB or RSV pneumonia varied ac-
cording to GA. For infants ≤32 weeks, 33-35 weeks,
and ≥37 weeks GA, intubation was required in 21.4%,
8.7%, and 12.1% of cases, respectively [101]. Co-infection
increased the risk of intubation in children ≤2 years of age
with RSV-induced AB (10% vs. 7.5% for not co-infected
children) [31].
The use of antibiotics varied according to age and pre-
sence of comorbidity. The 13.6% of AB patients ≤2 years
of age received antibiotics [30]. In patients with RSV infec-
tion as the only respiratory infectious agent, antibiotics
were administered to 24.9% of children ≤18 months old
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and 46.8% of children over 18 months old [26]. In the
U.S., whereas only 9% of elderly patients with no related
comorbidity received antibiotics, its administration
reached 43% among high-risk adults [22].
The 64.7% of AB patients ≤2 years of age were treated
with short acting inhalers of β2- adrenergic agonist [30].
However, U.S. studies report lower usage, with only 4%
of healthy elderly and 29% of high-risk adults receiving
this treatment [22].
Corticoids were administered to children with RSV-
induced AB orally (16.8%), via inhalation (4.8%), or par-
enteral (5.8%) [30]. There were reports of 21% of
RSV-infected high-risk adults receiving parenteral corti-
coids [22]. It is possible that part of the of antibiotics,
corticoids, and bronchodilators prescription may be due
to overuse by lack of adherence to clinical practice
guideline recommendations.
The 27.6% of AB pediatric cases required antipyretics
[30]. Higher usage has been reported in RSV-infected
adult patients over 65 years of age with no comorbidity
(46%) than in high-risk adults (32%) [22].
Economic impact
The economic studies reviewed were mostly focused on
assessing the effiency of palivizumab for the prophylaxis
of RSV infection. Assessments were based on a decision-
making model based on the existing literature [55,57-60],
analyses of a U.S. nationally representative database
[51], or systematic literature reviews [61-63]. Four of
the studies examined contributed data on direct costs
(DC) for years 2000, 2005 and 2006 [51,58-60], and
three provided data on indirect costs (IC) for years 2005
and 2006 [58-60].
Direct and indirect costs
Direct costs of an AB episode in infants ≤35 weeks GA
have been estimated at 466€, and at 2,134€ when inclu-
ding subsequent recurrent wheezing episodes [58]. In in-
fants <32 weeks GA, costs increased as GA decreased. DC
estimates reached 1,169€ per acute episode and 5,608€
when also treating recurrent wheezing [59]. A 2006 study
estimated the DC of acute episodes at 421€ in children
32 to 35 weeks GA with two associated risk factors
[60]. Finally, in the U.S., the hospitalization costs per
child ≤5 years of age with RSV were estimated at $4,584
[60]. Corresponding indirect costs estimated in these three
studies for children not on palivizumab prophylaxis were:
3.159€ [58], 4.634€ [59], and 1.768€ [60].
Impact on quality of life
Recurrent wheezing after RSV-induced AB negatively
impacts children’s quality of life [103]. The authors mea-
sured quality of life with a validated questionnaire with
13 dimensions and found a negative impact not only in
the respiratory system dimension, but also in the one
related to gastrointestinal tract and sleep quality. Quality
of life is worse during the winter months, when whee-
zing episodes tend to increase.
Strategies to reduce the impact of RSV infection
Social factors
Home overcrowding (≥4 adults), school-age siblings, go-
ing to daycare, exposure to tobacco smoke, and breast-
feeding period shorter than two months are some of the
risk factors for RSV infection requiring hospital admis-
sion [20,47,103]. Tobacco smoke exposure is also a risk
factor for increasing the length of hospital stays [20].
Hygienic measures
Parents must be informed of the basic hygienic habits that
help prevent spreading RSV infection, especially to highly
vulnerable preterm infants. Frequent hand washing and
isolation of RSV-infected patients have proven effective
means of reducing RSV nosocomial RSV infections [104].
Prophylactic treatment
Palivizumab is the only approved drug to prevent RSV-
induced ALRI and minimize complications. The study
IMpact-RSV observed a 55% (95% CI: 38%-72%) reduction
in hospitalizations after prophylaxis with palivizumab
(Number Needed to Treat, NNT = 17). The efficacy was
higher in children without BPD (78%; 95% CI: 66%-90%)
(NNT = 16) than in those with BPD (38%; 95% CI: 20%-
58%) (NNT = 20) [52,64]. In children with congenital
heart disease, palivizumab prophylaxis reduced RSV-
related hospital admission rates between 58% and 86%
[64]. Other studies have reported reductions in ICU
[64,65] and hospital [66] admission rates around 50% due
to palivizumab prophylaxis.
In addition, a substantial reduction in self-reported
incidence of recurrent wheezing was observed in in-
fants ≤35 weeks GA who received palivizumab prophy-
laxis when compared to controls (13% vs. 26%) as well as
in doctor-diagnosed incidence (8% vs. 16%). Prophylaxis
was also associated with a delay in the onset of wheezing
[105]. A recent clinical trial involving healthy preterm
infants 33-35 weeks GA treated for immunoprophylaxis
with palivizumab reported a relative risk reduction (RRR)
of 47% (95% CI: 14%-80%) in the proportion of children
with recurrent wheezing episodes and a reduction of 61%
(95% CI: 56%-65%) in the total number of days with
wheezing episodes during the infant’s first year [106].
The cost-effectiveness of RSV infection prophylaxis
with palivizumab varies substantially depending on the
patient group. A substantial portion of effectiveness
studies reviewed concluded that preterm infant prophy-
laxis, especially in those with associated risk factors, was
cost-effective in terms of the cost per Quality Adjusted
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Life Years (QALY) gained [57-60,62]. However, other
authors did not find it cost-effective in terms of costs
per avoided hospital admission [55,63]. Regardless, the
cost-effectiveness ratio was strongly associated to the
mortality rate of the reference group [61]. According to
the model proposed by Mahadevia et al. [57], prophy-
laxis was cost effective in preterm infants 32-35 weeks
GA and chronological age (CA) ≤6 months, with asso-
ciated risk factors. Effectiveness improved in preterm
infants 32-34 weeks GA and CA ≤3 months and, espe-
cially in children ≤32 weeks GA and CA ≤6 months.
Lázaro and colleagues [58] found an incremental cost-
effectiveness relationship (ICE) for medical direct costs,
including recurrent wheezing, of 13,846€ per QALY
(12,208€/QALY for preterm infants and 17,620€/QALY
for chronic lung disease (CLD)). In all cases, QALY was
well under the 30.000 €/QALY threshold which is the
generally socially acceptable standard in Europe. The
cost-effectiveness ratio was more favorable when indirect
costs were included. Thus, authors concluded that pali-
vizumab was a cost-effective treatment to protect high-
risk children against RSV.
Discussion
For the most part, available population-based data on
RSV are estimates based on analyses of administrative
databases of hospital admissions or on review studies of
specific age groups or clinical condition. Incidence data
may be underestimated, however, both in children and
adults. For pediatric cases, for instance, where RSV in-
fection is most common, the majority of clinical guides
for AB management do not recommend the routine use
of diagnostic tests since diagnosis does not affect treat-
ment and only a small number of patients require
admission. Still, in hospitalized children, diagnosis may
be of interest in order to establish hospital cohorts when
isolation of the child is not feasible [108], or for epi-
demiological reasons.
RSV infection is rarely diagnosed in adults because the
clinical presentation tends to be non-specific and easily
mistaken for an influenza outbreak. Further, physicians
avoid requesting the more complex diagnostic tests
required for adults such as the RT-PCR (reverse trans-
cription polymerase chain reaction) and/or blood tests
[22,50]. Despite the potential underestimation bias, the
incidence rate found in studies such as Falsey et al. is
relevant being twice that of influenza A, with a similar
disease burden in terms of hospital stays and mortality
in high-risk adults [22].
The clinical presentation of RSV infection in children
and adults varies significantly. In children the most com-
mon presentation is AB. In full term children without
comorbidities the presentation tends to be benign and
resolves in a few days, although between 2% and 3% do
require admission. In preterm children or with cardiore-
spiratory comorbidity, the risk of hospitalization as well as
complications, especially respiratory ones such as apnea,
increase substantially and even full term and comorbidity-
free children frequently suffer AOM as a complication.
In healthy adults the clinical presentation for RSV may
mirror that of influenza, with similar consequences. RSV
infection has often been involved in exacerbations of
COPD. The importance of preventing viral infection in
these patients is based on avoiding the greater physical
decline, greater hospitalization rates, and longer recovery
time that viral exacerbation episodes bring compared to
the exacerbations caused by bacterial infections [40].
The childhood mortality risk associated to RSV infec-
tion is almost negligible, except in children with severe
associated morbidity for whom 25% mortality rate has
been reported. Mortality rates in adults and the elderly
are similar to that of influenza, except in hospitalized
populations with mortality rates up to 80% [22].
The use of diagnostic and treatment resources for RSV
infection acute episodes contribute substantially to the
disease’s burden on healthcare costs. According to findings
from a multicenter study by González de Dios and col-
leagues [30] the most frequently performed diagnostic tests
on children are: oxygen saturation (3 out of 4 children),
RSV rapid diagnostic test and chest X-ray (one third of
children), and blood count (1 out of 5 children). However,
the study failed to specify where the tests were performed.
Based on other studies, one could assume that most of the
tests were performed in the emergency room although a
large portion of the chest X-rays may have been prescribed
in primary care [51].
Data on diagnostics and treatment for RSV infection in
adults are scarce in general and non-existent for Spain.
Based on the limited information found we concluded that
chest X-ray is a common diagnostic tool, especially among
patients with cardiopulmonary comorbidity [22].
Over half of children admitted with RSV-induced re-
spiratory infection require oxygen therapy. And a signifi-
cant number (between 1 and 5 in 10) require assisted
ventilation due to recurrent apneas, hypoxemia, in-
creased work of breathing, and respiratory failure
[47,49,56]. The need for intubation is greater in children,
especially preterm infants (1 in 5 infants ≤32 GA is intu-
bated) or co-infected with RV (1 in 10 ≤ 2 years of age).
Unfortunately, there is lack of consensus regarding the
best type of ventilatory support [67].
Estimating the use of oxygen therapy in adults due to
RSV infection is a difficult task because in many cases the
patients had COPD and were already using this therapy.
Studies report that a substantial proportion of these pa-
tients (up to 1 in 10) required assisted ventilation [22,24].
Although RSV infection is viral, antibiotics are often
used even in the absence of bacterial co-infection. In
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Spain, one fourth of pediatric patients ≤18 months and
half of those >18 months received antibiotics. No data
on Spain adults were found, but in the U.S. antibiotics
were prescribed to half of the high-risk patients and to 1
in 10 patients with no related comorbidity.
The use of other drugs such as bronchodilators was
fairly common, especially in children. In Spain, they
were used by two thirds of children ≤2 years of age with
RSV-induced AB [30]. In the U.S., thirty percent of
high-risk adults were treated with bronchodilators [22].
Although the effectiveness of corticoids is not proven in
children with AB [67], their use is not uncommon in
Spain, especially administered orally and, to a lesser
extent, through inhalation or parenterally (1 in 20) [30].
In the U.S., 1 in 4 high-risk adults are treated with
parenteral corticoids [22].
The impact of RSV on medical resources goes beyond
hospital admissions, diagnostic tests, and treatments
necessary to manage infection-related episodes. For in-
stance, the volume of follow-up primary care visits
following RSV infection is significant [22,51]. Data are
likely to be underestimated, however, due to lack of
accounting of visits related to medium- and long-term
respiratory complications. Recent findings by Shefali-Patel
et al. [34] suggest that primary care visits during the two
years following the first RSV infection-related episode in
infants 32-35 weeks GA almost doubled that of controls.
One of the potential complications of RSV infection are
abnormalities in the spirometric flow which are 5 times
more likely in children with a history of RSV infection
than in controls and which risk may not subside for
20 years after the initial episode [85]. Other potential com-
plications are recurrent wheezing (3 times more likely
than in controls [41,42,86,87]) and asthma, with a 20-fold
risk during the first few months post initial episode
compared to controls [93]. Although the risk of asthma
decreases with time, it remains four times higher than in
controls even after reaching adulthood [45]. Evidence on
the causal relationship between RSV infection and asthma
remains inconclusive. For some authors, the greater sensi-
tivity to environmental allergens after RSV infection may
be explained by having common risk factors, such as gen-
etic predisposition. This hypothesis finds support in a twin
study that concluded that the association between severe
RSV infection and asthma was bidirectional [68]. How-
ever, studies using prophylactic treatment of RSV with
palivizumab have shown a 50% reduction in recurrent
wheezing rates compared to controls [69,105,106] which
suggest a causal relationship between RSV infection and
asthma. Finally, another common medium-term compli-
cation, such as allergic rhino-conjunctivitis, may also con-
tribute to the greater primary care usage.
RSV infection in children also has a substantial impact
on visits to the specialist. Visits more than double in
preterm children and those with cardiorespiratory
disease [41]. Regarding emergency services, Shefali-Patel
and colleagues found that children with a history of RSV
infection are over three times more likely to use the
emergency room in the two years following infection
than those never infected [34]. In the U.S., a third of
high-risk adults and one fifth of those without comor-
bidities reported visiting a specialist due to RSV in-
fection. In contrast, visits to the emergency room were
relatively low (one in 10 high-risk adults and none
among adults with no comorbidities) [22].
Data collected here on hospitalization rates and length
of stay in children infected with RSV vary substantially
not only due to the difference among age groups and co-
morbidity levels but also due to the differing characteris-
tics of healthcare systems across countries. For instance,
estimating the hospitalization rate for all ages from stud-
ies performed in Spain is problematic. Results from a
survey of Spanish hospitals, emergency services, primary
care centers, and doctor offices [30] show that 34.6% of
over 5,000 AB episodes were admitted, that RSV diag-
nostic tests were performed in one third of all episodes,
and that 63% were positive for the virus. However, the
method of collecting and reporting data in Spain pre-
vents the estimation of hospitalization rate due to RSV.
Carbonell and colleagues [48] reported a 13% admission
rate for children <32 GA, the highest rate reported in
children with this GA. This result, when combined with
Spanish data on average length of hospital stay due to
RSV infection in children <2 years of age (5-8 days)
[21,29], is more than twice that reported in U.S. or U.K.
[20,56] and suggests that the Spanish admission rate
may be one of the highest reported.
In the U.S. rates also vary by comorbidity levels and
estimates show that one in six of high-risk adults are
admitted [22]. Although no other data are available, that
we are aware of, we would have expected higher rates.
In Spain, ICU admission is rare for children with no
comorbidities but it may be necessary for almost one
third of those with congenital heart disease hospitalized
with RSV infection, a comorbidity that may extend the
length of stay from 4 to 10 days [21]. In U.S. adults, one
in six high-risk patients required admission to the ICU
[22], and for patients >50 years of age the average ICU
stay was 5 days [24].
Estimated DC found in the literature support the in-
formation we found on healthcare resources dedicated
to treating the acute phase of RSV infection episode in
children as well as the mid- to long-term complications.
Average DC to treat the acute episode is four times
lower than the costs related to the following recurrent
wheezing episodes, regardless of the child’s age [58,59].
From a social perspective indirect costs should be taken
into account, which are similar to the costs related to
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the sequelae of recurrent wheezing episodes according
to the studies reviewed [58,59].
To our knowledge, there are no cost-effectiveness
studies examining the economic burden of RSV infec-
tion. In contrast with the negligible RSV-related child
mortality, mortality in hospitalized adults may reach 8%
[22], an important factor to consider when estimating
the economic burden of the disease. Another under-
studied aspect is the medium- and long-term conse-
quences with or without COPD. Thus, the costs and
real economic impact of RSV infection in adults, espe-
cially high-risk adults, is an area in need of further
research.
Interventions to prevent RSV infection are unable to
encompass all the social risk factors. Several of these
factors are not easily amenable to change such as the
number of adults living in the household, siblings
attending school, or daycare attendance. However,
interventions could increase general knowledge on RSV
infection mechanisms and factors such exposure to to-
bacco smoke, breastfeeding duration, and hygienic mea-
sures, as well as the management of high-risk patients.
The effectiveness of palivizumab in reducing admis-
sion rates, ICU length of stay, and morbidity in children
with or without related risk factors has been demon-
strated [52,64]. However, its high cost and the almost
negligible children mortality has limited its use to treat
children with risk-factors [70]. Estimates derived from
effectiveness models in preterm high-risk infants are
under the accepted threshold of 30,000€/QALY, thus,
the use of palivizumab falls within the socially accep-
table range of financing by public health care systems
[58-60]. However, no studies have been found on the
cost effectiveness of prophylactic treatment among
high-risk adults despite two important factors affecting
this population: a. mortality rates are not negligible; and
b. the burden of disease as a result of the medium- and
long-term consequences of RSV infection is likely to be
as substantial as for high-risk children.
Conclusions
Based on the results of this review, we conclude that:
 The health impact of RSV infection is significant
and goes beyond the acute episode phase.
 The health impact of RSV infection on children is
much better documented than on adults.
 Further research is needed on the medium- and
long-term impact of RSV infection on the adult
population, especially those high-risk.
 There is a need for interventions aimed at reducing
the impact of RSV infection by targeting health
education, information, and prophylaxis in high-risk
populations.
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